Hope springs eternal: are we yet ready for a novel paradigm shift in lipid-lowering therapy in primary prevention?-Reference-Cited by-同舟云学术

Hope springs eternal: are we yet ready for a novel paradigm shift in lipid-lowering therapy in primary prevention?

Published:2024-04-10 Issue:10 Volume:31 Page:1214-1215
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:

Author:

De Buyzere Marc L¹^ORCID

Affiliation:

1. Cardiology Department, University Hospital UZ Ghent , Corneel Heymanslaan 10, Ghent 9000 , Belgium

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwae140/57334113/zwae140.pdf

Reference9 articles.

1. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomized, open-label, non-inferiority trial;Kim;Lancet,2022

2. Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape;Pedicino;Eur Heart J,2022

3. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study;Jun;Eur J Prev Cardiol,2024

4. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: a meta-analysis of randomized controlled studies;Ah;PLoS One,2022

5. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) compared with up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk of coronary heart disease;Conard;Am J Cardiol,2008